Cookies used for improved website experience

Siemens Healthineers and our partners use cookies and other similar technologies to operate the Siemens Healthineers websites and personalize content and ads. You may find out more about how we use cookies by clicking "Show details" or by referring to our Cookie Policy.
You may allow all cookies or select them individually. And you may change your consent and cookie preferences anytime by clicking on the "Review and change your consent" button on the Cookie Policy page.

Moving the Needle on Fentanyl-Related Deaths

Moving the Needle on Fentanyl-related DeathsThe Need for a Multi-pronged Approach

Over 60 million people struggle with the addictive effects of opioids globally, and more than 100,000 people die every year of opioid overdose, many of them due to fentanyl.1 As the rates continue to increase, new harm reduction and overdose prevention strategies are necessary to help communities mitigate this ongoing crisis.

A new white paper describes the current gaps and opportunities related to fentanyl testing necessary to improve and support local overdose prevention efforts.

The use of FDA-approved fentanyl urine drug screens within dedicated and healthcare populations is important for identifying at-risk individuals and populations and vital in identifying local trends and responding to changing needs to help alter the trajectory of the overdose epidemic.